Literature DB >> 15191335

Pituitary tumor apoplexy: characteristics, treatment, and outcomes.

Meg Verrees1, Baha M Arafah, Warren R Selman.   

Abstract

Pituitary tumor apoplexy is an uncommon event heralded by abrupt onset of severe headache, restriction of visual fields, deterioration of visual acuity, and weakness of ocular motility frequently coupled with clinical indications of decreased endocrine function. Hemorrhage into or necrosis of a preexisting sellar mass, usually a pituitary macroadenoma, produces an expansion of sellar contents. Compression of adjacent structures elicits the variable expression of symptoms referable to displacement of the optic nerves and chiasm and impingement of the third, fourth, and sixth cranial nerves. Damage to or destruction of the anterior pituitary leads to multiple acute and/or chronic hormone deficiencies in many patients. Medical management may be used in rare cases in which the signs and symptoms are mild and restricted to meningismus or ophthalmoplegia deemed to be stable. In patients with visual or oculomotor lability or an altered level of consciousness, expeditious surgical decompression, accomplished most commonly through a transsphenoidal approach, should be performed to save life and vision and to optimize the chance of regaining or maintaining pituitary function.

Entities:  

Mesh:

Year:  2004        PMID: 15191335     DOI: 10.3171/foc.2004.16.4.7

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  46 in total

1.  Third, Fourth, and Sixth Cranial Nerve Palsies in Pituitary Apoplexy.

Authors:  Rabih Hage; Sheila R Eshraghi; Nelson M Oyesiku; Adriana G Ioachimescu; Nancy J Newman; Valérie Biousse; Beau B Bruce
Journal:  World Neurosurg       Date:  2016-07-17       Impact factor: 2.104

2.  Pituitary apoplexy in an adrenocorticotropin-producing pituitary macroadenoma.

Authors:  Serap Baydur Sahin; S Cetinkalp; M Erdogan; U Cavdar; G Duygulu; F Saygili; C Yilmaz; A G Ozgen
Journal:  Endocrine       Date:  2010-07-14       Impact factor: 3.633

3.  Visual outcome after transsphenoidal surgery in patients with pituitary apoplexy.

Authors:  Ju-Wan Seuk; Choong-Hyun Kim; Moon-Sul Yang; Jin-Hwan Cheong; Jae-Min Kim
Journal:  J Korean Neurosurg Soc       Date:  2011-06-30

4.  Encephalopathy, Chiasmal Compression, Ophthalmoplegia, and Diabetes Insipidus in Pituitary Apoplexy.

Authors:  Meghan Berkenstock; Alexander Szeles; Jessica Ackert
Journal:  Neuroophthalmology       Date:  2014-09-19

5.  Surgical treatment for severe visual compromised patients after pituitary apoplexy.

Authors:  Chi-Cheng Chuang; Chen-Nen Chang; Kuo-Chen Wei; Cheng-Chih Liao; Peng-Wei Hsu; Ying-Cheng Huang; Yao-Liang Chen; Li-Ju Lai; Ping-Ching Pai
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

6.  A retrospective review of 34 cases of pediatric pituitary adenoma.

Authors:  Nannan Zhang; Peizhi Zhou; Yu Meng; Feng Ye; Shu Jiang
Journal:  Childs Nerv Syst       Date:  2017-07-18       Impact factor: 1.475

7.  Effect of transsphenoidal surgery on decreased visual acuity caused by pituitary apoplexy.

Authors:  Naoya Takeda; Katsuzo Fujita; Shigenori Katayama; Nobuyuki Akutu; Shigeto Hayashi; Eiji Kohmura
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

8.  Governor Pio Pico, the monster of California...no more: lessons in neuroendocrinology.

Authors:  Ivan S Login; Jessica Login
Journal:  Pituitary       Date:  2010       Impact factor: 4.107

Review 9.  Bilateral cerebral infarction in the setting of pituitary apoplexy: a case presentation and literature review.

Authors:  Christopher Banerjee; Brian Snelling; Simon Hanft; Ricardo J Komotar
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 10.  Pituitary apoplexy: considerations on a single center experience and review of the literature.

Authors:  L Giammattei; G Mantovani; G Carrabba; S Ferrero; A Di Cristofori; E Verrua; C Guastella; L Pignataro; P Rampini; M Minichiello; M Locatelli
Journal:  J Endocrinol Invest       Date:  2016-01-05       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.